WilmerHale Represents Pandion Therapeutics in $58M Series A Financing
On January 18, 2018, Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, announced its $58 million Series A financing. Pandion intends to use the proceeds to advance tissue-specific immune modulator drugs for autoimmune and inflammatory diseases. The round was led by Polaris Partners, Versant Ventures, and Roche Venture Fund, with from SR One and BioInnovation Capital.
The WilmerHale team representing Pandion included Lia Der Marderosian, Stephanie Singer, Andrea Sorrentino and Howell Ma.
Read Pandion's press release.